glp 1 nafld SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease Liver-targeting drugs and their effect

In HCC driven by obesity and nonalcoholic steatohepatitis, the downregulation of CPT2 leads to the accumulation of acylcarnitines, among which C18:1-carnitine enhances spheroid formation by HCC cells through STAT3 activation, indicating that the accumulation of acylcarnitine can promote the development of liver cancer [212]

Both cholesterol and triglyceride management are factors associated with cardiovascular health

503B outsourcing facilities make our drug supply more resilient, but 81% of 503Bs newly registered since June 2021 have never been inspected by FDA staff

Most GLP-1 medications provide guidance for missed doses in the prescribing information

Only the math changed